RxSight (NASDAQ:RXST) Stock Price Up 1.6% – What’s Next?

RxSight, Inc. (NASDAQ:RXST)’s stock price traded up 1.6% during mid-day trading on Wednesday . The company traded as high as $47.40 and last traded at $46.79. 49,971 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 486,818 shares. The stock had previously closed at $46.06.

Analysts Set New Price Targets

RXST has been the topic of a number of research analyst reports. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Company cut their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Oppenheimer lowered their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Finally, Jefferies Financial Group initiated coverage on RxSight in a research note on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $61.63.

RxSight Stock Up 0.7 %

The company has a fifty day moving average price of $48.85 and a two-hundred day moving average price of $52.44.

Insider Activity at RxSight

In other news, Director Jesse Anderson Corley purchased 11,111 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $45.37 per share, with a total value of $504,106.07. Following the completion of the transaction, the director now owns 468,571 shares of the company’s stock, valued at $21,259,066.27. The trade was a 2.43 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00. Following the completion of the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $2,247,064.74. This trade represents a 6.84 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,702 shares of company stock valued at $3,059,197. Insiders own 9.36% of the company’s stock.

Institutional Investors Weigh In On RxSight

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in RxSight by 2.7% during the first quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock worth $78,634,000 after buying an additional 40,500 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of RxSight by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 60,908 shares of the company’s stock worth $3,143,000 after acquiring an additional 994 shares during the last quarter. California State Teachers Retirement System raised its stake in RxSight by 6.8% in the 1st quarter. California State Teachers Retirement System now owns 27,052 shares of the company’s stock valued at $1,395,000 after acquiring an additional 1,733 shares during the period. CWM LLC lifted its holdings in RxSight by 727.5% during the 2nd quarter. CWM LLC now owns 422 shares of the company’s stock valued at $25,000 after purchasing an additional 371 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in RxSight during the second quarter worth $3,754,000. 78.78% of the stock is owned by institutional investors.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.